A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma in Vitro and in Vivo.
Authors:
- Dimitrios FilioglouDFDimitrios Filioglou
- Nina Santa-CruzNSNina Santa-Cruz
- Geovana Sf LeiteGLGeovana Sf Leite
- Dan W DaviniDDDan W Davini
- Megan J CracchioloMCMegan J Cracchiolo
- Forrest L BakerForrest L Baker
- Muhammad HusnainMHMuhammad Husnain
- Richard J SimpsonRSRichard J Simpson
- Vasilios VoudourisVVVasilios Voudouris
- Emmanuel KatsanisEmmanuel Katsanis
Preprint
- 19 May 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Bendamustine (BEN) combined with Rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formu-lation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we in-vestigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 in-hibitor Venetoclax (VEN) and/or the oral BTKi acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. BEN induced significant cyto-toxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrat-ed limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Overall, our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.Keywords
All Related Versions
- Version 1, 2025-05-19, Preprints
- Published version: Cancers, 17 (11), 1889.
This publication has 55 references indexed in Scilit:
- Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignanciesBritish Journal of Clinical Pharmacology, 2025
- Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignanciesCancer Chemotherapy and Pharmacology, 2024
- Recent advances in genomics and therapeutics in mantle cell lymphomaCancer Treatment Reviews, 2023
- Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphomaCancer Chemotherapy and Pharmacology, 2023
- A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in JapanCancer Chemotherapy and Pharmacology, 2022
- Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell LymphomaClinical Therapeutics, 2019
- Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experienceAnnals of Hematology, 2014
- Anticancer oral therapy: Emerging related issuesCancer Treatment Reviews, 2010
- Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphomaCancer Chemotherapy and Pharmacology, 2010
- Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphomaLeukemia Research, 2006